FreeBioList

Catalysts / ALT

Altimmune (ALT) catalysts

Upcoming FDA decisions and readouts we track for Altimmune, each with the filing that announced it.

Listed on — Nasdaq Catalysts tracked — 1 Rows last checked — 12 Sep 2026

FreeBioList tracks 1 upcoming catalyst for Altimmune (ALT, listed on Nasdaq). It concerns Pemvidutide (Alcohol-associated liver disease).

First on the list: the Phase 2 readout for Pemvidutide (Alcohol-associated liver disease), guided by the company to H2 2027.

The row links to an SEC filing (8-K or 6-K). It has been verified by a person reading the filing itself, most recently on 12 Sep 2026. The methodology page explains each status.

Background reading: Clinical trial phases explained: Phase 1 to Phase 4.

Ticker
ALT
Next catalyst
H2 2027
Type
Phase 2 readout
Listed options
Yes
Company ▾ Drug ▾ Effect / indication Next catalyst ▾ Phase / type ▾ Status ▾ Source Options
Altimmune ALT · Nasdaq Pemvidutide Alcohol-associated liver disease H2 2027
company guidance		 Phase 2 readout Verified 8-K exhibit 99.1 ↗ Yes